In a long, 600 paragraph decision, the Federal Court held that one of three patents for a formulation of adalimumab, a monoclonal antibody used in treating various autoimmune diseases, was valid and being infringed upon by a biosimilar product, SIMLANDI.

This appeal concerned a decision of the Federal Court that dismissed allegations by the appellant, Sandoz Canada Inc. (“Sandoz”), that Canadian Patent No. 2,659,770 (the “770 Patent”) was invalid.

This appeal concerned an allegation by the respondents, Janssen Inc. and Actelion Pharmaceuticals Ltd. (collectively, “Janssen”), that the marketing and sale by the appellant, Apotex Inc.

IFIT sued Safe Sweat for trademark infringement in Federal Court by way of application. The relief sought by IFIT includes damages, or alternatively, an accounting of profits. The parties served their affidavit evidence.

The self-represented plaintiff appealed an order of the Case Management Judge, in which the CMJ had dismissed the plaintiff’s motion to compel the defendants to answer questions on discovery.

NCS claimed that the Kobold group of companies, and their tool supplier Promac Industries, infringed five patents related to downhole tools and sleeves for fracking.

This legal dispute involved SOCAN (Society of Composers, Authors, and Music Publishers of Canada) and Québecor Inc., with SOCAN representing copyright holders and Québecor as the defendant.

Certification motion denied in copyright infringement case

This cost assessment follows a successful case for the plaintiffs, Janssen Inc. and Janssen Pharmaceutica N.V. (“Janssen”) for a patent infringement case (2022 FC 1218), where the Court ordered a cost assessment by an Assessment Officer (the “AO”).

Seismotech IP Holdings Inc (hereinafter “Seismotech”/plaintiff) made a claim against unknown defendants (“John Does”) in Canada and in the US, as well as the domestic and foreign manufacturers (“reverse class actions”), for infringement of its patent related to intelligent thermostats.